Should I buy or sell Renalytix stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Renalytix in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RNLX shares. View RNLX analyst ratings or view top-rated stocks .

What is Renalytix's stock price target for 2024?

1 analysts have issued twelve-month price objectives for Renalytix's shares. Their RNLX share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 533.7% from the stock's current price. View analysts price targets for RNLX or view top-rated stocks among Wall Street analysts .

How have RNLX shares performed in 2024?

Renalytix's stock was trading at $0.39 on January 1st, 2024. Since then, RNLX stock has increased by 102.3% and is now trading at $0.7890. View the best growth stocks for 2024 here .

When is Renalytix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, June 14th 2024. View our RNLX earnings forecast .

How were Renalytix's earnings last quarter?

Renalytix Plc (NASDAQ:RNLX) posted its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09). The business earned $0.71 million during the quarter, compared to analyst estimates of $0.70 million. Renalytix had a negative net margin of 1,736.47% and a negative trailing twelve-month return on equity of 1,008.88%.

What other stocks do shareholders of Renalytix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix investors own include Trevena (TRVN) , Advanced Micro Devices (AMD) , ChromaDex (CDXC) , Chimerix (CMRX) , CTI BioPharma (CTIC) , DRDGOLD (DRD) , Forte Biosciences (FBRX) .

When did Renalytix IPO?

Renalytix (RNLX) raised $156 million in an IPO on Friday, July 17th 2020. The company issued 11,000,000 shares at $14.22 per share. J.P. Morgan and Stifel acted as the underwriters for the IPO.

How do I buy shares of Renalytix?

Shares of RNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RNLX

Renalytix (RNLX) Stock Price, News & Analysis

→ Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report (From Darwin) (Ad)

Free RNLX Stock Alerts

$0.79

-0.04 (-4.83%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.73
▼
$0.83
50-Day Range: $0.38
▼
$1.47
52-Week Range: $0.24
▼
$4.04

Volume: 209,438 shs
Average Volume: 1.66 million shs
Market Capitalization: $39.43 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Get Renalytix alerts:

Renalytix MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 533.7% Upside
$5.00 Price Target
Short Interest: Healthy
1.59% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

Computer And Technology Sector

411th out of 590 stocks

Medical Laboratories Industry

13th out of 19 stocks

3.5

Analyst's Opinion

Consensus Rating
Renalytix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Renalytix has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.59% of the outstanding shares of Renalytix have been sold short.
Short Interest Ratio / Days to Cover
Renalytix has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Renalytix has recently decreased by 11.11%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Renalytix does not currently pay a dividend.
Dividend Growth
Renalytix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RNLX.

1.4

News and Social Media Coverage

News Sentiment
Renalytix has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Computer and Technology companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Renalytix this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for RNLX on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Renalytix to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Renalytix insiders have not sold or bought any company stock.
Percentage Held by Insiders
18.30% of the stock of Renalytix is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 9.92% of the stock of Renalytix is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Renalytix is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Renalytix is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Renalytix has a P/B Ratio of 5.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Special FREE offer on stock hotsheets

These sheets tell you the exact day you should consider buying a stock… And the exact day you should consider selling it… All based on TEN YEARS of historic data and trends. For example, like January 6th through the 12th with Apple… It’s gone up every single year for the last decade. Or like May 26th through June 11th with LULU… Again - it’s gone up every single year for the last decade. Then there’s July 1st through the 21st with Walmart… What happened to WMT?

Click here and I’ll show you

About Renalytix Stock (NASDAQ:RNLX)

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

RNLX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RNLX Stock News Headlines

April 17, 2024 | msn.com

Renalytix files to sell 19.99M ordinary shares for holders

April 9, 2024 | marketwatch.com

Renalytix Sells Stock to Raise Up to $4 Mln

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 8, 2024 | globenewswire.com

Renalytix Announces Financing with Expected Size of up to $4 Million

March 25, 2024 | investorplace.com

3 Ridiculously Enticing Stocks to Buy for Under a Buck

March 14, 2024 | stockhouse.com

KidneyIntelX(TM) included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)

March 14, 2024 | globenewswire.com

KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)

March 12, 2024 | msn.com

Google restricts election queries by AI model Gemini - report

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

March 12, 2024 | msn.com

New Zealand air-safety authorities to seize flight recorders for Latam 787

March 5, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Renalytix AI Amidst Potential Acquisition and Strong Market Prospects

March 4, 2024 | msn.com

Why Is AI-Powered Diagnostic Firm Renalytix Stock Soaring On Monday?

March 4, 2024 | msn.com

Renalytix approached by potential buyer, stock rallies 28%

February 29, 2024 | msn.com

Why Is Kidney-Disease Diagnostic Focused Renalytix Stock Trading Higher Today?

February 24, 2024 | msn.com

Renalytix Plc - Depositary Receipt () (RNLX) Price Target Increased by 21.81% to 5.97

February 15, 2024 | finance.yahoo.com

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

February 15, 2024 | globenewswire.com

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

February 13, 2024 | msn.com

U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.33%

February 12, 2024 | msn.com

Renalytix surges after Medicare draft decision on lead product

February 11, 2024 | msn.com

Wall Street Set to Open Modestly Higher as S&P Hovers Just Above 5,000

February 10, 2024 | markets.businessinsider.com

Renalytix AI Anticipates Medicare Coverage Milestone

February 9, 2024 | markets.businessinsider.com

Strong Buy for Renalytix AI: Undervalued Stock with Promising Market Prospects and Strategic Growth Catalysts

February 9, 2024 | globenewswire.com

Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 10, 2024 | finance.yahoo.com

New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease

December 31, 2023 | markets.businessinsider.com

BTIG Keeps Their Buy Rating on Renalytix AI (RNLX)

December 30, 2023 | benzinga.com

Renalytix Stock (NASDAQ:RNLX) Dividends: History, Yield and Dates

November 14, 2023 | finanznachrichten.de

Renalytix plc: Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024

See More Headlines

Receive RNLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/18/2024
Next Earnings (Estimated): 6/14/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Computer and Technology
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:RNLX
CUSIP: N/A
CIK: 1811115
Web: www.renalytixai.com
Phone: 44-20-3139-2910
Fax: N/A
Employees: 102
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +536.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-45,610,000.00
Net Margins: -1,736.47%
Pretax Margin: -1,736.18%
Return on Equity: -1,008.88%
Return on Assets: -155.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.59
Quick Ratio: 0.59

Sales & Book Value

Annual Sales: $3.40 million
Price / Sales: 11.54
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.15 per share
Price / Book: 5.23

Miscellaneous

Outstanding Shares: 49,970,000
Free Float: 40,821,000
Market Cap: $39.23 million
Optionable: Optionable
Beta: 3.03

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. James R. McCullough M.B.A. (Age 56)
Chief Executive Officer
Comp: $1.04M
Mr. Thomas H. McLain CPA (Age 65)
M.B.A, President
Comp: $662.7k
Mr. Oliver James Sterling III
Chief Financial Officer
Mr. Fergus Fleming (Age 56)
Chief Technology Officer
Dr. Michael J. Donovan M.D. (Age 69)
Ph.D., Chief Medical Officer
Mr. Howard B. Doran Jr. (Age 63)
Chief Business Officer
Mr. Salim Gulamabbas Hamir F.C.A.
Company Secretary

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RNLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Renalytix stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Renalytix in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RNLX shares.
View RNLX analyst ratings or view top-rated stocks.
What is Renalytix's stock price target for 2024?: 1 analysts have issued twelve-month price objectives for Renalytix's shares. Their RNLX share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 533.7% from the stock's current price.
View analysts price targets for RNLX or view top-rated stocks among Wall Street analysts.
How have RNLX shares performed in 2024?: Renalytix's stock was trading at $0.39 on January 1st, 2024. Since then, RNLX stock has increased by 102.3% and is now trading at $0.7890.
View the best growth stocks for 2024 here.
When is Renalytix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, June 14th 2024.
View our RNLX earnings forecast.

How were Renalytix's earnings last quarter?: Renalytix Plc (NASDAQ:RNLX) posted its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09). The business earned $0.71 million during the quarter, compared to analyst estimates of $0.70 million. Renalytix had a negative net margin of 1,736.47% and a negative trailing twelve-month return on equity of 1,008.88%.
What other stocks do shareholders of Renalytix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix investors own include Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC), DRDGOLD (DRD), Forte Biosciences (FBRX).
When did Renalytix IPO?: Renalytix (RNLX) raised $156 million in an IPO on Friday, July 17th 2020. The company issued 11,000,000 shares at $14.22 per share. J.P. Morgan and Stifel acted as the underwriters for the IPO.
How do I buy shares of Renalytix?: Shares of RNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RNLX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial